
    
      This study will help determine whether the occurrence of adverse events can be decreased by
      moving to a bi-weekly, opposed to a weekly, dosing schedule of gemcitabine plus nab-Pacitaxel
      for the treatment of unresectable/metastatic pancreatic cancer.
    
  